Monitoring the effects of disease-modifying drugs on the health of people with multiple-sclerosis - Assessing the relevance of antibodies to interferon-beta and Copaxone

Trial Profile

Monitoring the effects of disease-modifying drugs on the health of people with multiple-sclerosis - Assessing the relevance of antibodies to interferon-beta and Copaxone

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Glatiramer acetate (Primary) ; Interferon beta (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Jun 2013 Planned End Date changed from 1 Aug 2015 to 1 Jun 2013 as reported by United Kingdom Clinical Research Network record.
    • 16 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 27 Jan 2013 Accrual to date is 64% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top